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Dear Editor:
We would like to report an interesting case of a man suffering
from both ulcerative colitis (UC) and toxic epidermal
necrolysis (TEN) at the same time. We are aware that such
cases are already described in medical literature. However,
previous articles perceive TEN as an adverse effect of deriv-
atives of 5-aminosalicyclic acid (5-ASA), which are the foun-
dation of conservative management of UC. In our patient, UC
was diagnosed postmortem so he did not receive any drugs for
UC at the time his cutaneous symptoms appeared. We believe
it to be the first report of such co-existence without involve-
ment of 5-ASA.
The described patient was a 49-year-old man with left kid-
ney agenesia, suffering from type 2 diabetes and chronic con-
stipation. Surgical history included appendectomy and lapa-
rotomy due to fecal obstruction of the sigmoid colon nine
years before. His constant medications were as follows:
acetylosalicylic acid 75 mg 1×, propranolol 40 mg 2×,
glimepiride 4 mg 1×, metformin 1000 mg 3×, vinpocetine
10 mg 2×, piracetam 1200 mg 2×, and pridinol 5 mg 2×.
In late 2012, he developed slowly expanding bullae.
Ambulatory management with glucocorticoid (i.v./i.m.
dexametasone 4 mg) was administered but unsuccessful.
Due to unknown etiology of his condition and ineffectiveness
of empiric treatment, he was admitted in early 2013 to the
Department of Dermatology of Wroclaw Medical University
(WMU). Upon admission, multiple small and large bullae
filled with serous fluid were present on all of the patient’s skin.
Mucosae were not affected. Since day one of hospitalization,
the patient had no bowel movement.
Series of laboratory, radiological, and pathomorphologic
tests were performed. Laboratory tests revealed the following:
(1) elevated inflammatory markers (WBC 28,400/μl, CRP
84.5 mg/l) and eosinophilia (11.2 %) in peripheral blood
smear, (2) decreased level of total plasma protein (5.2 g/dl)
and albumin (3.3 g/dl), (3) slightly decreased level of vitamin
B12 and folic acid, but no anemia (RBC 5,670,000/μl, HGB
16.7 g/dl, HCT 46.6 %), (4) dyslipidemia (HDL cholesterol
23 mg/dl, triglycerides 240 mg/dl), and (5) bad metabolic
control of diabetes (glycemia up to 459 mg/dl, HbA1C
7.1 %, glycosuria 500 mg/dl). Tumor markers (CA15-3,
CA19-9, CEA, PSA, AFP, and CA125) as well as
virusological studies were negative: anti-HBe (−), anti-HBs
level normal, anti-HCV (−), and anti-HBc (+). Chest X-ray
showed no abnormalities.
Direct immunofluorescence (DIF) study of skin sample
was performed. Linear concretions of C3c along the basement
membrane zone (BMZ) and additionally sparse fine-grained
concretions of IgM along BMZ were discovered. There were
no IgG, IgA, or C1q concretions. The result of DIF study
suggested the diagnosis of pemphigoid. Histopathological ex-
amination of skin sample was also performed. It revealed vast
subepidermal bullae, which might have indicated
pemphigoid.
After diagnosing pemphigoid, systemic treatment with sul-
fone (dapsone 50 mg, than 100 mg daily) and i.v. glucocorti-
coid (methylprednisolone 250 mg—2 doses at the fifth and
ninth day) as well as local dressings (sulfathiazole with silver,
hydrocortisone, oxytetracycline) were applied. Pain-
management involved paracetamol and tramadol. Glycemia
was controlled by metformin (1000 mg 3×) and glimepiride
(4 mg); the latter was then switched to insulin (intermediate-
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and short-acting). Other medications taken by the patient be-
fore hospitalization were sustained.
At the eighth day of hospitalization, progression of cutane-
ous condition was observed. Extensive epidermal exfoliation,
as in TEN, as well as new bullae involving about 60 % of the
body area appeared. New lesions spread also to mucosae,
which might correspond with clinical manifestation of TEN
(Lyell syndrome). Dapsone and propranolol therapy, the most
suspected of causing TEN, was discontinued. Second DIF
result was identical. Immunosuppressant (cyclosporine 200–
0–100 mg p.o., than 100–0–50 mg i.v.) and antibiotics (ceftri-
axone 1000 mg 1× i.v.) were introduced, thus stopping the
progression of lesions.
After nine days of hospitalization, the patient still had no
bowel movement; in addition, he vomited several times.
Consulting internist reinstated propranolol (20 mg 2×) and
added metoclopramide (10 mg p.o. or i.v. 2–3×) and glycerol
suppositories. Consulting anesthesiologist performed venous
blood gases examination (pH 7.43, pCO2 34.8 mmHg, pO2
54.6 mmHg, sO2 88.9 %). Consulting surgeon described the
abdomen as non-tender, with no peritoneal signs, no masses,
and present peristaltic sounds. Conservative treatment was
recommended, consisting of strict diet, i.v. fluids, electrolytes
supplementation, pantoprazole (40 mg 2×), metoclopramide
(10 mg 3×), an enema, and abdomen X-ray in standing
position.
Increase of abdomen circumference and symptoms of sub-
acute bowel obstruction appeared. Prokinetic drugs, further
enemas, and gastric tube were ordered. During the following
days, patient’s condition did not improve. Abdomen CT
showed distension of the colon and aroused a suspicion of
fecalith in the sigmoid colon. Other organs showed no
abnormalities.
Due to progression of symptoms of bowel obstruction, the
patient was transferred to the Department of General Surgery
of WMU at the 12th day of hospitalization and operated at the
same day. Laparotomy revealed the distended small intestine
with multiple adhesions, enormous distension of the entire
colon (diameter about 15 cm) filled with feces as well as the
thickened and inflamed colonic wall with no haustra. In spite
of both features of toxic megacolon and irreversibility of co-
lonic pathology, subtotal colectomy with terminal ileostomy
was performed. After procedure, the patient developed acute
circulatory and respiratory insufficiency and was transferred
to the Department of Intensive Care ofWMU. During the next
several hours, symptoms of septic shock appeared.
In the Department of Intensive Care, multidisciplinary
treatment was applied including the following: (1) supplemen-
tation of fluids and electrolytes, albumin infusions, (2) blood
transfusions, (3) catecholamines, (4) management of acute
renal failure (loop diuretics, discontinuation of cyclosporine,
continuous venovenous hemodiafiltration (CVVHDF)), (5)
antibiotics, (6) parenteral and enteral nutrition, (7)
antithrombotic agents, (8) continuous insulin infusion, (9)
dressings with potassium iodide and greasing agents. During
several days, patient’s condition stabilized, requirement for
vasopressors decreased, and hemodiafiltration was no longer
necessary. After initial improvement, symptoms of septic
shock reappeared and signs of circulatory failure and levels
of inflammatory markers increased, despite antimicrobial
treatment. At the 26th day of hospitalization, the patient de-
veloped multi-organ failure (MOF) and eventually died at the
27th day of hospitalization.
Histopathological examination of specimen revealed ne-
crosis of the colon mucosa about 80 cm in length (total length
140 cm). Pathologist diagnosed active UC and chronic inflam-
mation of the surrounding tissues and greater omentum aswell
as present nervous ganglia in the colon wall (that excluded
potentially possible diagnosis of late Hirschprung disease).
Immunohistochemical study was positive for S-100 marker.
UC may be accompanied by various pathologies of other
organs, which are called extraintestinal complications. They
occur in about 30% of patients and manifest themselves in the
joints, eyes, and skin. Cutaneous complication is divided into
reactive, specific, nutrition-related, and others. Reactive com-
plicat ion includes erythema nosodum, pyoderma
gangrenosum, aphthous ulcers of oral cavity, and necrotic
vasculitis.
TEN is a severe pathology of the skin and mucosa.
Erythema, bullae, and epidermal exfoliation are present.
Severe TEN may be accompanied by inflammation of the
mucosa, mostly in proximal part of the digestive tract. UC-
like pathology was never described as a part of Lyell syn-
drome. Etiology of TEN is immunological, and in most cases,
TEN itself is a reaction to infection or drug. Nonetheless, in
some cases, the provoking factor remains unknown. The list
of drugs that may induce TEN includes antibiotics (trimetho-
pr im-sul famethoxazole and other sul fonamides ,
aminopenicillins, cephalosporins, and quinolones), anti-
convulsive drugs (carbamazepine, phenytoin, and phenobar-
bital), allopurinol, and II generation of NSAIDs (coxibs). Our
patient did not receive any of the above prior to first skin
lesions.
TEN, as well as its milder form, and Stevens–Johnson syn-
drome (SJS) have not been considered as being extraintestinal
manifestations of UC before. Very few cases of co-existence
of TEN and UC are described in the medical literature. The
Medline database contains three such publications in English.
In all three papers, treatment of UCwith derivatives of 5-ASA
was pointed out as a cause of TEN. None of them suggests a
direct relation between these conditions nor treats TEN as an
extraintestinal complication of UC. Appearance of TEN may
be triggered by a lot of drugs, and the actual prevalence of
TEN in patients treated with 5-ASA is very low.
The question remains whether cutaneous lesions were
linked to digestive tract pathology in the case of our patient.
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Wewere not able to determine whether toxic megacolon devel-
oped as a complication of TEN or whether the patient had
suffered UC before, which symptoms were masked by severe
TEN. Dermatological symptoms may have also preceded de-
velopment of severe onset of UC. Could TEN be viewed as an
extraintestinal manifestation of UC or was this just a random
coincidence and bullous lesions were a reaction to unknown
antigen? Toxic megacolon might also have been a consequence
of patient’s severe general condition or developed as the most
severe form of mucosal lesions in TEN. Moreover, imposition
of two severe conditions made both proper evaluation of diges-
tive tract pathology and its treatment very difficult. The present-
ed issue requires further observation. Perhaps collection of a
greater number of individual cases in the future will allow us to
describe the exact interference between UC and TEN.
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